Trial Profile
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Cemiplimab (Anti-PD-1) and Other Agents in Japanese Patients With Advanced Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; Fianlimab (Primary) ; Gemcitabine; Ipilimumab; Paclitaxel; Pemetrexed
- Indications Advanced breast cancer; Bladder cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Uterine cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Regeneron Pharmaceuticals
- 14 Sep 2023 Planned number of patients changed from 117 to 145.
- 14 Sep 2023 Planned End Date changed from 24 May 2026 to 27 Mar 2030.
- 14 Sep 2023 Planned primary completion date changed from 24 May 2026 to 22 Dec 2027.